David Bond, MD
Hematology · Columbus, OHNPI 1114288859
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,673 of the $30,085 with a category attached, or 82.0%. 8 manufacturers reported payments, led by ADC Therapeutics America, Inc. at 36.5% of the total. Reporting peaked in 2023 at $10,980 and has fallen 83.1% since, to $1,859 in 2025.
Across 41 payments — averaging $733.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$11K
- Seagen Inc.$10K
- Novartis$3K
- Gilead$3K
- Incyte Corporation$2K
- AstraZeneca$154
- plus $208 from 2 others
Across 92 payments — averaging $25,029 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$680K
- Pfizer$352K
- Beone Medicines Ltd.$342K
- Gilead$236K
- Adaptive Biotechnologies Corporation$187K
- Novartis$149K
- plus $357K from 6 others
What the payments were for
- Consulting fees$24,67382%
- Speaking & faculty fees$1,5005%
- Travel & lodging$2,1857%
- Food & beverage$1,7286%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 8 | $10,984 |
| Seagen Inc. | 14 | $10,337 |
| Novartis | 11 | $3,493 |
| Gilead | 2 | $3,260 |
| Incyte Corporation | 1 | $1,650 |
| AstraZeneca | 2 | $154 |
| Genmab U.S., Inc. | 2 | $133 |
| Genentech USA, Inc. | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,085 in reported general payments places this provider in the 70th percentile of 84 hematology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 52 | $776,850 |
| EliquisApixaban | 22 | $12,025 |
| ValacyclovirValacyclovir Hcl | 15 | $144 |
| Allopurinol | 12 | $54 |
Paid to pharmacies, not to this prescriber.
Other hematology in Columbus
- Uma BorateColumbus$323K
- Sam PenzaColumbus$256K
- Spero CatalandColumbus$245K
- Kami MaddocksColumbus$236K
- Narendranath EpperlaColumbus$199K
- Yvonne EfeberaColumbus$169K
- Naresh BummaColumbus$109K
- Kerry RogersColumbus$100K
- Jennifer WoyachColumbus$73K
- Hannah ChoeColumbus$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.